This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Pierre Fabre Medicament. Active years: 2007-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007-2013
Title: Stéphane Cuisiat: Innovator in Medical Chemistry
Introduction
Stéphane Cuisiat is a notable inventor based in Castres, France. He has made significant contributions to the field of medical chemistry, particularly through his innovative patents. With a total of three patents to his name, Cuisiat's work focuses on the development of compounds that have potential therapeutic applications.
Latest Patents
Cuisiat's latest patents include groundbreaking inventions such as derivatives of aminocyclobutane or aminocyclobutene. These compounds are characterized by a general formula that includes various substituents, which can be utilized as medical products. Another significant patent involves 3-(cyclopenten-1-yl)-benzyl or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives, which are aimed at treating schizophrenia. This invention outlines a method of treatment that involves administering these compounds, showcasing Cuisiat's commitment to addressing complex medical challenges.
Career Highlights
Stéphane Cuisiat is currently associated with Pierre Fabre Medicament, a company known for its focus on pharmaceutical innovations. His work at this institution has allowed him to explore and develop new medicinal compounds that can significantly impact patient care.
Collaborations
Cuisiat collaborates with esteemed colleagues such as Bernard Vacher and Wouter Koek. These partnerships enhance the research and development process, fostering an environment of innovation and shared expertise.
Conclusion
Stéphane Cuisiat stands out as a prominent figure in the realm of medical chemistry, with his patents reflecting a deep understanding of complex chemical compounds. His contributions have the potential to lead to significant advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
